share_log

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(10.7%),Johnson & Johnson Innovation-JJDC, Inc.(10.7%)

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals

强生 | SC 13G：超过5%持股股东披露文件
美股sec公告 ·  04/10 17:17
Moomoo AI 已提取核心信息
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on April 10, 2024, indicating a significant ownership stake in Contineum Therapeutics, Inc. The filing reveals that Johnson & Johnson Innovation-JJDC, Inc. beneficially owns 1,979,173 shares of Contineum Therapeutics' Class A Common Stock, which represents 10.7% of the class. This ownership level was based on the number of shares outstanding after Contineum Therapeutics' initial public offering on April 9, 2024. The filing was made pursuant to Rule 13d-1(c) and indicates that the shares are not held with the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect.
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on April 10, 2024, indicating a significant ownership stake in Contineum Therapeutics, Inc. The filing reveals that Johnson & Johnson Innovation-JJDC, Inc. beneficially owns 1,979,173 shares of Contineum Therapeutics' Class A Common Stock, which represents 10.7% of the class. This ownership level was based on the number of shares outstanding after Contineum Therapeutics' initial public offering on April 9, 2024. The filing was made pursuant to Rule 13d-1(c) and indicates that the shares are not held with the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect.
强生通过其子公司强生创新-JJDC, Inc. 于2024年4月10日向美国证券交易委员会提交了附表13G，表明Contineum Therapeutics, Inc.拥有大量所有权。该文件显示，强生创新-JJDC, Inc.实益拥有Contineum Therapeutics的1,979,173股A类普通股，占该类别的10.7％。该所有权水平基于Contineum Therapeutics于2024年4月9日首次公开募股后的已发行股票数量。该申报是根据第13d-1（c）条提交的，表明持有股份的目的不是为了改变或影响发行人的控制权，也不是与具有此类目的或效力的任何交易有关。
强生通过其子公司强生创新-JJDC, Inc. 于2024年4月10日向美国证券交易委员会提交了附表13G，表明Contineum Therapeutics, Inc.拥有大量所有权。该文件显示，强生创新-JJDC, Inc.实益拥有Contineum Therapeutics的1,979,173股A类普通股，占该类别的10.7％。该所有权水平基于Contineum Therapeutics于2024年4月9日首次公开募股后的已发行股票数量。该申报是根据第13d-1（c）条提交的，表明持有股份的目的不是为了改变或影响发行人的控制权，也不是与具有此类目的或效力的任何交易有关。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息